Pfizer Inc. Stock
€22.98
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 0.150% | 0.679% | 5.535% | -8.811% | 7.965% | -41.982% | -17.222% |
| BioMarin Pharmaceutical Inc. | -1.610% | -3.933% | 8.349% | -21.067% | 1.729% | -46.486% | -19.321% |
| AbbVie Inc. | -0.620% | -0.105% | 2.476% | -1.643% | -3.055% | 31.492% | 113.118% |
| Biogen Inc. | -1.110% | -2.360% | 9.334% | 18.836% | 6.306% | -37.773% | -29.498% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of Pfizer Inc. (PFE), a major player within the pharmaceuticals industry, a mixed picture starts to emerge. On the one hand, the company boasts a solid revenue stream and demonstrates a commendable operating margin, creating an impression of profitability. On the other hand, several warning signs appear in the form of declining growth metrics and concerns over income stability. Now, let’s break down the analysis into pros and cons to provide a comprehensive view.
Strong Revenue Performance: Pfizer reported a total revenue of approximately $54.89 billion over the trailing twelve months. This figure suggests that the company has maintained a robust sales figure, driven largely by their pharmaceutical portfolio, including well-known products and newly developed vaccines.
Healthy Operating Margins: The operating margin, standing at around 31.63%, illustrates the company's efficiency in turning sales into profit. This is relatively strong for the pharmaceutical sector, indicating that Pfizer is effectively managing its operating expenses relative to its revenue.
Comments
News
This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income
Pfizer (NYSE: PFE) is one of the world's largest and most respected pharmaceutical companies. That is an important backdrop for dividend investors to consider as they look at the stock's lofty 6.4%
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
On February 17, 2026, Perceptive Advisors reported a buy of Celcuity (NASDAQ:CELC), adding 203,881 shares in the fourth quarter, with an estimated transaction value of $16.76 million based on
Massive News: Pfizer's 6% Dividend Could Be Safer Than You Think
Pfizer (NYSE: PFE) offers a rare mix of scale, stability, and a 6% dividend yield that few large caps can match. With steady cash flow, modest valuation, and analyst upside, this defensive giant may